Oli, a wireless, wearable device that monitors maternal and fetal signals, has secured $6.5 million in funding to accelerate development of its technology and support regulatory and clinical progress across Australia and the United States ahead of launch.

Oli，一款监测母婴信号的无线可穿戴设备，已获得650万美元的融资，以加速其技术开发，并在上市前推动在澳大利亚和美国的监管和临床进展。

The funding will support the completion of pivotal clinical trials underway across seven sites in Australia and the United States, advancement of regulatory submissions with the Therapeutic Goods Administration (TGA) and the US Food and Drug Administration (FDA), as well as business operations, and the establishment of manufacturing operations and headquarters in Australia..

这笔资金将用于支持在澳大利亚和美国七个地点进行的关键临床试验的完成，推动与澳大利亚治疗用品管理局 (TGA) 和美国食品药品监督管理局 (FDA) 的监管提交工作，同时也将用于业务运营以及在澳大利亚建立制造业务和总部。

The Series A3 round, backed by Scale Investors, Clare Ventures and The University of Sydney, follows a $1.8 million Series A2 in 2024 and a $4.7 million Series A in 2022. To date, Oli has raised $13 million in private capital, alongside more than $9.5 million in non-dilutive grants.

由Scale Investors、Clare Ventures和悉尼大学支持的A3轮融资，是在2024年完成180万美元的A2轮融资和2022年完成470万美元的A轮融资之后进行的。迄今为止，Oli已筹集了1300万美元的私人资本，以及超过950万美元的非稀释性拨款。

Oli aims to have the ability to analyse up to fifteen conditions and complications across pregnancy and birth, including postpartum haemorrhage (PPH), fetal distress, stillbirth risk and labour progression.

奥利旨在具备分析怀孕和分娩过程中多达十五种状况和并发症的能力，包括产后出血（PPH）、胎儿窘迫、死产风险和分娩进展等。

Oli’s dual-market strategy positions Australia as a key launchpad for clinical adoption and innovation, while targeting the significant scale opportunity in the United States, where rising maternal mortality and PPH rates are driving urgent demand for data-driven, preventative care solutions.

奥利的双市场战略将澳大利亚定位为临床应用和创新的关键起点，同时瞄准美国的巨大规模机遇，美国因孕产妇死亡率和产后出血率上升，正迫切需求数据驱动的预防性护理解决方案。